Article Text

Download PDFPDF
1152 Treatment strategies in stage IVB endometrial cancer patients: insights from a comprehensive single-institution experience
  1. Matteo Loverro1,
  2. Vincenzo Tarantino2,
  3. Emanuele Perrone3,
  4. Eleonora Palluzzi4,
  5. Giovanni Scambia5 and
  6. Francesco Fanfani6
  1. 1Department of Obstetrics and Gynecology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
  2. 2Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy
  3. 3Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
  4. 4Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
  5. 5Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
  6. 6Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy


Introduction/Background In stage IVB endometrial carcinoma (EC), the role of cytoreductive surgery in determining prognosis is pivotal, despite the absence of robust evidence from randomized clinical trials. However, primary surgery may not be suitable due to underlying health conditions or disease burden. In these patients, current evidence supporting neoadjuvant treatment (NACT) is limited. This study aims to assess the survival impact of NACT followed by interval surgery (IDS) compared to patients undergoing primary resection (PDS).

Methodology We retrospectively identified all patients with stage IVB EC who underwent both PDS and IDS, from January 2012 to December 2022 at our institution. For each patient we categorized metastatic disease spread (abdominal and distant) and intraperitoneal location (pelvic, mesogastric and upper abdominal).

Results Among 196 identified patients, 77 had endometrioid EC, and 119 had non-endometrioid tumors. Metastases were limited to the abdomen in 163 cases, 33 patients had distant metastasis. Disease extended above the pelvic rim in 73% of cases, the upper abdomen was involved in 47.2% of cases.

PDS was performed in 82.2% of cases, IDS in 17.8%. Complete gross resection was achieved in 86.7% of cases.

Extra-abdominal disease, upper abdominal carcinomatosis, and ascites were identified as independent predictive factors for receiving NACT.

PDS and NACT approaches showed comparable overall survival(OS), with a median OS of 34 versus 26 months(p=0.120), even in patients with extra-abdominal metastasis(p=0.796). Similar results were observed for patients with upper abdominal disease (median OS 28 versus 26 months, respectively, p=0.092).

Multivariate analysis identified extra-pelvic peritoneal location of disease (HR: 1.844, CI: 1.129–3.013, p=0.015) and residual tumor (HR: 1.778, CI: 1.058–2.987, p=0.030) as independent poor prognostic factors for OS.

Conclusion NACT followed by IDS is a viable treatment alternative for unresectable stage IVB EC. Extra-abdominal metastasis should not preclude surgical cytoreduction. Post-operative residual tumor and extra-pelvic carcinomatosis significantly impact survival.

Disclosures Nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.